Inflammation and immune system contribution to the etiology of atherosclerosis: Mechanisms and methods of assessment

Nursing Research

Volumn 63, Issue 5, 2014, Pages 375-385

  Salisbury, Dereck ^a   Bronas, Ulf ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

atherosclerosis; cardiovascular disease; immune system; inflammation; nursing research

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; HUMAN; IMMUNOLOGY; INFLAMMATION; LIPID METABOLISM; METABOLISM; PATHOPHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; LIPID METABOLISM; LIPOPROTEINS, LDL;

EID: 84907030410     PISSN: 00296562     EISSN: 15389847     Source Type: Journal    
DOI: 10.1097/NNR.0000000000000053     Document Type: Review

References (72)

1. Abbate, A., Van Tassell, B.W., & Biondi-Zoccai, G. G. L. (2012). Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. BioDrugs, 26, 217-233. doi:10.2165/ 11631570-000000000-00000
2. Abeywardena, M. Y., Leifert, W. R., Warnes, K. E., Varghese, J. N., & Head, R. J. (2009). Cardiovascular biology of interleukin-6. Current Pharmaceutical Design, 15, 1809-1821. doi:10.2174/13816 1209788186290
3. Ait-Oufella, H., Sage, A. P.,Mallat, Z., & Tedgui, A. (2014). Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circulation Research, 114, 1640-1660. doi:10.1161/ CIRCRESAHA.114.302761
4. Bevilacqua, M. P., & Nelson, R. M. (1993). Selectins. Journal of Clinical Investigation, 91, 379-387. doi:10.1172/JCI116210
5. Biemond, B. J., Levi, M., Ten Cate, H., Van der Poll, T., Büller, H. R., Hack, C. E., & Ten Cate, J. W. (1995). Plasminogen activator and plasminogen activator inhibitor 1 release during experimental endotoxaemia in chimpanzees: Effect of interventions in the cytokine and coagulation cascades. Clinical Science, 88, 587-594. doi:10.1042/cs0880587
6. Bisoendial, R. J., Kastelein, J. J. P., & Stroes, E. S. G. (2007). C-reactive protein and atherogenesis: From fatty streak to clinical event. Atherosclerosis, 195, e10-e18. doi:10.1016/j.atherosclerosis.2007.04.053
7. Blankenberg, S., Barbaux, S., & Tiret, L. (2003). Adhesion molecules and atherosclerosis. Atherosclerosis, 170, 191-203. doi:10.1016/ S0021-9150(03)00097-2
8. Brevetti, G., Schiano, V., & Chiariello, M. (2006). Cellular adhesion molecules and peripheral arterial disease. Vascular Medicine, 11, 39-47. doi:10.1191/1358863x06vm645ra
9. Bruunsgaard, H., Pedersen, M., & Pedersen, B. K. (2001). Aging and proinflammatory cytokines. CurrentOpinion in Hematology, 8, 131-136
10. Canat, X., Carayon, P., Bouaboula, M., Cahard, D., Shire, D., Roque, C., Casellas, P. (1993). Distribution profile and properties of peripheral-type benzodiazepine receptors on human hemopoietic cells. Life Sciences, 52, 107-118. doi:org/10.1016/0024-3205(93) 90293-C
11. Cesari, M., Penninx, B. W. J. H., Newman, A. B., Kritchevsky, S. B., Nicklas, B. J., Sutton-Tyrrell, K., Pahor, M. (2003). Inflammatory markers and onset of cardiovascular events: Results from the health ABC study. Circulation, 108, 2317-2322. doi:10.1161/01.CIR.0000097109.90783.FC
12. Csiszar, A., Wang, M., Lakatta, E. G., & Ungvari, Z. (2008). Inflammation and endothelial dysfunction during aging: Role of NF-kappaB. Journal of Applied Physiology, 105, 1333-1341. doi:10.1152/ japplphysiol.90470. 2008
13. De Jager, S. C. A., & Kuiper, J. (2011). Vaccination strategies in atherosclerosis. Thrombosis and Haemostasis, 106, 796-803. doi:10.1160/TH11-05- 0369
14. De Jager, W., Bourcier, K., Rijkers, G. T., Prakken, B. J., & Seyfert- Margolis, V. (2009). Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunology, 10, 52. doi:10.1186/1471-2172-10-52
15. Di Gregoli, K., & Johnson, J. L. (2012). Role of colony-stimulating factors in atherosclerosis. Current Opinion in Lipidology, 23, 412-421. doi:10.1097/MOL.0b013e328357ca6e
16. Fähnrich, K. A., Pravda, M., & Guilbault, G. G. (2001). Recent applications of electrogenerated chemiluminescence in chemical analysis. Talanta, 54, 531-559. doi:S0039-9140(01)00312-5
17. Ferri, C., Croce, G., Cofini, V., De Berardinis, G., Grassi, D., Casale, R., Desideri, G. (2007). C-reactive protein: Interaction with the vascular endothelium and possible role in human atherosclerosis. Current Pharmaceutical Design, 13, 1631-1645. doi:10.2174/ 138161207780831301
18. Forster, R. J., Bertoncello, P., & Keyes, T. E. (2009). Electrogenerated chemiluminescence. Annual Review of Analytical Chemistry, 2, 359-385. doi:10.1146/annurev-anchem-060908-155305
19. Gaemperli, O., & Kaufmann, P. A. (2012). Hybrid CCTA/IVUS: Breaking the traditional boundaries of coronary imaging. European Heart Journal, 33, 941-943. doi:10.1093/eurheartj/ehs006
20. Gerszten,R. E.,Garcia-Zepeda, E.A., Lim, Y.-C.,Yoshida, M.,Ding, H.A., Gimbrone,M. A. Jr., Rosenzweig, A. (1999).MCP-1and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature, 398, 718-723. doi:10.1038/19546
21. Glass, C. K., & Witztum, J. L. (2001). Atherosclerosis: The road ahead. Cell, 104, 503-516
22. Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines.( 2010). 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation, 122, 2748-2764. doi:10.1161/CIR.0b013e3182051bab
23. Griendling,K.K.,& Alexander, R.W. (1997). Oxidative stress and cardiovascular disease. Circulation, 96, 3264-3265
24. Hansson, G. K. (2005). Inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine, 352, 1685-1695. doi:10.1056/ NEJMra043430
25. Hunt, K. J., Walsh, B. M., Voegeli, D., & Roberts, H. C. (2010a). Inflammation in aging part 1: Physiology and immunological mechanisms. Biological Research for Nursing, 11, 245-252. doi:10.1177/1099800409352237
26. Hunt, K. J.,Walsh, B.M., Voegeli, D., & Roberts, H. C. (2010b). Inflammation in aging part 2: Implications for the health of older people and recommendations for nursing practice. Biological Research for Nursing, 11, 253-260. doi:10.1177/1099800409352377
27. Joshi, F., Rosenbaum, D., Bordes, S., & Rudd, J. H. F. (2011). Vascular imaging with positron emission tomography. Journal of Internal Medicine, 270, 99-109. doi:10.1111/j.1365-2796.2011.02392.x
28. Kakkar, A. K., & Lefer, D. J. (2004). Leukocyte and endothelial adhesion molecule studies in knockout mice. Current Opinion in Pharmacology, 4, 154-158. doi:10.1016/j.coph.2004.01.003
29. Keller,C., Steensberg,A., Hansen,A.K., Fischer, C. P.,Plomgaard, P., & Pedersen, B. K. (2005). Effect of exercise, training, and glycogen availability on IL-6 receptor expression in human skeletal muscle. Journal of Applied Physiology, 99, 2075-2079. doi:10.1152/ japplphysiol.00590.2005
30. Khan,M.M., Liu,Y.,Khan,M.E.,Gilman,M.L.,Khan,S.T.,Bromberg,M.,& Colman, R. W. (2010). Upregulation of tissue factor in monocytes by cleaved high molecular weight kininogen is dependent on TNF-alpha and IL-1beta. American Journal of Physiology: Heart and Circulatory Physiology, 298, H652-H658. doi:10.1152/ajp heart.00825.2009
31. Kleinbongard, P., Heusch, G., & Schulz, R. (2010). TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacology & Therapeutics, 127, 295-314. doi:10.1016/j.pharmthera.2010.05.002
32. Lagrand, W. K., Visser, C. A., Hermens, W. T., Niessen, H. W. M., Verheugt, F.W. A., Wolbink, G.-J., & Hack, C. E. (1999). C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?. Circulation, 100, 96-102. doi:10.1161/01.CIR.100.1.96
33. Lamare, F.,Hinz, R.,Gaemperli,O., Pugliese, F.,Mason, J.C., Spinks,T., Rimoldi, O. E. (2011). Detection and quantification of largevessel inflammation with 11C-(R)-PK11195 PET/CT. Journal of Nuclear Medicine, 52, 33-39. doi:10.2967/jnumed.110.079038
34. Leng, S. X., McElhaney, J. E.,Walston, J. D., Xie, D., Fedarko, N. S., & Kuchel, G. A. (2008). ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. The Journals of Gerontology Series A: Biological Sciences andMedical Sciences, 63, 879-884
35. Libby, P. (2002). Inflammation in atherosclerosis. Nature, 420, 868-874. doi:10.1038/nature01323
36. Libby, P.,Aikawa,M.,& Jain,M.K. (2006).Vascular endothelium and atherosclerosis. Handbook of Experimental Pharmacology, 176, 285-306
37. Libby, P., & Ridker, P. M. (2004). Inflammation and atherosclerosis: Role of C-reactive protein in risk assessment. American Journal of Medicine, 116, 9-16. doi:10.1016/j.amjmed.2004.02.006
38. Mehta, N. N., Torigian, D. A., Gelfand, J. M., Saboury, B., & Alavi, A.( 2012). Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). Journal of Visualized Experiments: JoVE, 63, e3777. doi:10.3791/3777
39. Moore, K. W., deWaal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001). Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology, 19, 683-765. doi:10.1146/annurev.immunol .19.1.683
40. National Institute ofNursing Research. (2011). Bringing science to life.NINR strategic plan (No. 11-7783).Bethesda,MD:National InstitutesofHealth
41. Nieman, D. C. (2012). Clinical implications of exercise immunology. Journal of Sport and Health Science, 1, 12-17. doi:10.1016/j.jshs.2012.04.004
42. Pasceri, V., Willerson, J. T., & Yeh, E. T. H. (2000). Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 102, 2165-2168. doi:10.1161/01.CIR.102.18.2165
43. Patel, K. D., Cuvelier, S. L.,& Wiehler, S. (2002). Selectins: Criticalmediators of leukocyte recruitment. Seminars in Immunology, 14, 73-81. doi:10.1006/smim.2001.0344
44. Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O. III., Criqui, M., Vinicor, F. (2003). Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107, 499-511. doi:10.1161/01.CIR.0000052939.59093.45
45. Pedersen, B. K. (2006). The anti-inflammatory effect of exercise: Its role in diabetes and cardiovascular disease control. Essays in Biochemistry, 42, 105-117. doi:10.1042/bse0420105
46. Pedersen, B. K. (2011). Muscles and their myokines. Journal of Experimental Biology, 214, 337-346. doi:10.1242/jeb.048074
47. Perrier, S., Darakhshan, F., & Hajduch, E. (2006). IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?. FEBS Letters, 580, 6289-6294. doi:10.1016/j.febslet.2006.10.061
48. Petersen, A. M. W., & Pedersen, B. K. (2005). The anti-inflammatory effect of exercise. Journal of Applied Physiology, 98, 1154-1162. doi:10.1152/japplphysiol.00164.2004
49. Petrovsky, N.,& Harrison, L. C. (1998). The chronobiology of human cytokine production. International Reviews of Immunology, 16, 635-649
50. Picchi, A., Gao, X., Belmadani, S., Potter, B. J., Focardi, M., Chilian, W. M., & Zhang, C. (2006). Tumor necrosis factor-a induces endothelial dysfunction in the prediabetic metabolic syndrome. Circulation Research, 99, 69-77. doi:10.1161/01.RES.0000229685.37402.80
51. Pugliese, F.,Gaemperli,O., Kinderlerer, A. R., Lamare, F., Shalhoub, J., Davies, A. H., Camici, P. G. (2010). Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/ computed tomography angiography. Journal of the American College of Cardiology, 56, 653-661. doi:10.1016/j.jacc.2010.02.063
52. Ridker, P. M. (2001). Role of inflammatory biomarkers in prediction of coronary heart disease. The Lancet, 358, 946-948. doi:10.1016/ S0140-6736(01)06112-8
53. Ridker, P. M. (2009). Testing the inflammatory hypothesis of atherothrombosis: Scientific rationale for the cardiovascular inflammation reduction trial (CIRT). Journal of Thrombosis and Haemostasis, 7, 332-339. doi:10.1111/j.1538-7836.2009.03404.x
54. Ridker, P. M., Rifai,N., Pfeffer,M., Sacks, F., Lepage, S., & Braunwald, E.( 2000). Elevation of tumor necrosis factor-a and increased risk of recurrent coronary events after myocardial infarction. Circulation, 101, 2149-2153. doi:10.1161/01.CIR.101.18.2149
55. Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011). Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). American Heart Journal, 162, 597-605. doi:10.1016/j.ahj.2011.06.012
56. Robertson, A.-K., Rudling, M., Zhou, X., Gorelik, L., Flavell, R. A., & Hansson, G. K. (2003). Disruption of TGF-β signaling in T cells accelerates atherosclerosis. Journal of Clinical Investigation, 112, 1342-1350. doi:10.1172/JCI18607
57. Ross, R. (1999). Atherosclerosis-An inflammatory disease. New England Journal ofMedicine, 340,115-126. doi:10.1056/NEJM199901143400207
58. Rus, F. G., Niculescu, F., & Vlaicu, R. (1991). Tumor necrosis factoralpha in human arterial wall with atherosclerosis. Atherosclerosis, 89, 247-254. http://dx.doi.org/10.1016/0021-9150(91)90066-C
59. Sauer,H.,& Wartenberg,M. (2008). Circulatingisoprostanes:Gatekeepers in the route from oxidative stress to vascular dysfunction. Circulation Research, 103, 907-909. doi:10.1161/CIRCRESAHA.108.187278
60. Schuett, H., Luchtefeld, M., Grothusen, C., Grote, K., & Schieffer, B.( 2009). How much is too much?. Interleukin-6 and its signalling in atherosclerosis. Thrombosis and Haemostasis, 102, 215-222. doi:10.1160/TH09-05- 0297
61. Silvera, S. S., Aidi, H. E., Rudd, J. H. F., Mani, V., Yang, L., Farkouh, M., Fayad, Z. A. (2009). Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis, 207, 139-143. doi:10.1016/j.atherosclerosis.2009.04. 023
62. Skoog, T., Dichtl, W., Boquist, S., Skoglund-Andersson, C., Karpe, F., Tang, R., Hamsten, A. (2002). Plasma tumour necrosis factor-a and early carotid atherosclerosis in healthy middle-aged men. EuropeanHeart Journal, 23, 376-383. doi:10.1053/euhj.2001 .2805
63. Stillie, R., Farooq, S. M., Gordon, J. R., & Stadnyk, A.W. (2009). The functional significance behind expressing two IL-8 receptor types on PMN. Journal of Leukocyte Biology, 86, 529-543. doi:10.1189/jlb.0208125
64. Thompson, P. L., Nidorf, S. M., & Eikelboom, J. (2013). Targeting the unstable plaque in acute coronary syndromes. Clinical Therapeutics, 35, 1099-1107. doi:10.1016/j.clinthera.2013.07.332
65. Toutouzas, K., Synetos, A., Nikolaou, C., Stathogiannis, K., Tsiamis, E., & Stefanadis,C. (2012).Microwave radiometry:Anewnon-invasivemethod for the detection of vulnerable plaque. Cardiovascular Diagnosis & Therapy, 2, 290-297. doi:10.3978/j.issn.2223-3652.2012.10.09
66. Tsimikas, S., Willerson, J. T.,& Ridker, P.M. (2006). C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. Journal of the American College of Cardiology, 47, C19-C31. doi:S0735-1097(05)03138-4
67. Van Tassell, B. W., Toldo, S., Mezzaroma, E., & Abbate, A. (2013). Targeting interleukin-1 in heart disease. Circulation, 128, 1910-1923. doi:10.1161/CIRCULATIONAHA.113.003199
68. Veenman L.,& Gavish,M. 2006). The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. Pharmacology & Therapeutics 110 503-524 doi:10 016/j.pharmthera.2005. 09.007
69. Walsh, N. P., Gleeson, M., Shephard, R. J., Gleeson, M., Woods, J. A., Bishop, N., Simon, P. (2011). Position statement. part one: Immune function and exercise. Exercise Immunology Review, 17, 6-63. https://dspace.lboro.ac.uk/ dspace-jspui/bitstream/2134/10584/ 6/Walsh%20et%20al%202011%20EIR-17-2011-Part- One.pdf
70. Wilson, P.W. F.,Pencina,M., Jacques,P., Selhub, J., D'Agostino, R. Sr.,& O'Donnell, C. J. (2008). C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circulation: Cardiovascular Quality and Outcomes, 1, 92-97. doi:10.1161/ CIRCOUTCOMES.108.831198
71. Zarbock, A., & Ley, K. (2009). Neutrophil adhesion and activation under flow.Microcirculation, 16, 31-42. doi:10.1080/10739680802350104
72. Zhou, X., Fragala, M. S.,McElhaney, J. E., & Kuchel, G. A. (2010). Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. Current Opinion in Clinical Nutrition and Metabolic Care, 13, 541-547. doi:10.1097/MCO.0b013e32833cf3bc